Further research, particularly human studies, is needed to validate these effects and to explore the mechanisms by which GLP1-FGF21 dual agonist pharmacotherapy may modulate fetuin-A through adiponectin to contribute to the management of metabolic and liver diseases. The gene discussed is ADIPOQ; the disease is liver disorder.